

SUVEN Life Sciences Ltd



News Release

SUVEN's quarterly revenues increase by 60%

PAT up by 51%; R&D spend at 16% of Revenue

HYDERABAD, INDIA (July 31, 2006) – SUVEN LIFE Science's Board of Directors meeting held today in Hyderabad announced that the **revenue increased by 60%** to Rs. 2562.50 lacs for the first quarter ending June 2006 compared to Rs. 1594.26 lacs for the corresponding quarter of the previous year. **PAT up by 51%** from Rs. 137.67 lacs to Rs. 208.32 lacs. The company's **exports up by 92%** from Rs 1081 lacs to Rs 2084 lacs.

Suven's major thrust on R&D in **Drug Discovery** continues with an expenditure of Rs. 399 lacs recording about **16% of total revenue** for the quarter.

The Board of Directors has recommended a **dividend of 50%** per annum for the financial year 2005-06, constituting Rs.1 per share.

Suven Life Sciences is a Hyderabad based Life Sciences Company, pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade. During the quarter ended June 06, Suven added one more customer under contract research program.

In its endeavor to become collaborative research partner (CRP) for global life science companies Suven embarked on new business model "Drug Discovery and Development Support Services" (DDDSS) with the onset of Intellectual Property Regime in India since January 2005. This model has resulted in Suven getting an award "Partner of Choice in Drug Discovery for CNS" by Frost & Sullivan in 2005. Under DDDSS business model Suven intend to provide services from preclinical through clinical development and clinical data management in addition to CRAMS for global pharmaceutical and life science companies.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 190 professionals with the state of the art infrastructure for Drug Discovery and development activities with 30 clinical research professionals and the front end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions,

dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;